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Effects of Blood Pressure Lowering on Cerebral White
Matter Hyperintensities in Patients With Stroke
The PROGRESS (Perindopril Protection Against Recurrent Stroke Study)
Magnetic Resonance Imaging Substudy
Carole Dufouil, PhD; John Chalmers, MD, PhD; Oguzhan Coskun, MD; Véronique Besançon, MD;
Marie-Germaine Bousser, MD; Pierre Guillon, PhD; Stephen MacMahon, PhD;
Bernard Mazoyer, MD, PhD; Bruce Neal, MD, PhD; Mark Woodward, PhD;
Nathalie Tzourio-Mazoyer, MD, PhD; Christophe Tzourio, MD, PhD;
for the PROGRESS MRI Substudy Investigators
Background—The prevalence of white matter hyperintensities (WMHs) detected on cerebral MRI is associated with
hypertension, but it is not known whether blood pressure lowering can arrest their progression. We report here the results
of an MRI substudy of PROGRESS (Perindopril Protection Against Recurrent Stroke Study), a randomized trial of
blood pressure lowering in subjects with cerebrovascular disease.
Methods and Results—The substudy comprised 192 participants who had a cerebral MRI both at baseline and after a mean
follow-up time of 36 months (SD6.0 months). At the first MRI, WMHs were graded with a visual rating scale from
A (no WMH) to D (severe WMH). Participants were assigned to a combination of perindopril plus indapamide (or their
placebos; 58%) or to single therapy with perindopril (or placebo). At the time of the second MRI, the blood pressure
reduction in the active arm compared with the placebo arm was 11.2 mm Hg for systolic blood pressure and 4.3 mm Hg
for diastolic blood pressure. Twenty-four subjects (12.5%) developed new WMHs at follow-up. The risk of new WMH
was reduced by 43% (95% CI 7% to 89%) in the active treatment group compared with the placebo group (P0.17).
The mean total volume of new WMHs was significantly reduced in the active treatment group (0.4 mm3 [SE0.8])
compared with the placebo group (2.0 mm3 [SE0.7]; P0.012). This difference was greatest for patients with severe
WMH at entry, 0.0 mm3 (SE0) in the active treatment group versus 7.6 mm3 (SE1.0) in the placebo group
(P0.0001).
Conclusions—These results indicate that an active blood pressure–lowering regimen stopped or delayed the progression
of WMHs in patients with cerebrovascular disease. (Circulation. 2005;112:1644-1650.)
Key Words: stroke  cerebrovascular disorders  magnetic resonance imaging  hypertension  trials
White matter hyperintensities (WMHs) are often ob-served on brain MRIs in elderly persons1–5 and in
patients with stroke.6–8 WMHs, which include areas of
demyelination as well as silent infarcts, are associated with
cognitive impairment or dementia,4,9–13 depression,14–16 and
gait disturbances.17,18 Apart from age, the main risk factors
for WMHs are vascular, particularly high blood pressure.1,2,4
Cross-sectional population-based MRI studies have shown a
positive linear relationship between blood pressure and se-
verity of WMHs.5,19 From these studies, it also appears that
people with uncontrolled hypertension have a higher preva-
lence of severe WMH than people without hypertension or
with controlled hypertension.
See p 1525
MRI follow-up studies have shown that the total load of
WMHs may increase over time but will never decrease.17,20,21
To date, it is not known whether it is possible to stop or delay
this progression. Because of the strong relationship between
blood pressure and WMH, it seems plausible that lowering
blood pressure would reduce the incidence of WMHs, al-
though this has never been demonstrated.8 To test this
hypothesis, we conducted the first MRI-based assessment of
WMHs in a substudy of a randomized trial of blood pressure
lowering in patients with a history of cerebrovascular disease,
the Perindopril Protection Against Recurrent Stroke Study
(PROGRESS).22
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Methods
Study Design and Participants
The design of the PROGRESS study has been described in detail
elsewhere.22 Briefly, 6105 participants were recruited from 172
collaborating centers in 10 countries between May 1995 and No-
vember 1997. Participants were eligible if they had a history of
cerebrovascular disease (stroke or transient ischemic attack but not
subarachnoid hemorrhage) within the previous 5 years. In addition,
participants were required to have no clear indication for (such as
heart failure) or contraindication to treatment with an ACE inhibitor.
Active treatment comprised a flexible treatment regimen based on
perindopril (4 mg daily), with the addition of indapamide (2.5 mg
daily, or 2 mg daily in Japan) in those participants for whom the
responsible study physician believed that there was no specific
indication for nor contraindication to the use of a diuretic. Those
participants assigned placebo received tablets identical in appearance
to the active agents. The rationale for the use of combination therapy
(perindopril and indapamide or double placebo) rather than single-
drug therapy (perindopril or single placebo), wherever possible, was
to optimize the fall in blood pressure.
The cerebral MRI substudy was initiated in France in 1995. The
St. Antoine ethical committee approved the study, and all patients
signed an informed consent. The exclusion criteria included the usual
contraindications for MRI, such as prosthetic valves, pacemakers,
cerebral aneurysm clips, and a history of intraocular metal fragments,
cochlear implants, or claustrophobia. To be eligible, a center needed
to have a MRI scanner available and to be able to export the native
data. Ten centers were eligible and agreed to participate. Of the 322
patients (159 in the placebo group, 163 in the active treatment group)
randomized in these 10 centers, 281 (87%) volunteered to participate
(141 in the placebo group, 140 in the active treatment group), but of
these, 9 died before their MRI appointment and 18 met 1 of the
exclusion criteria (Figure 1). The remaining 254 patients (131 in the
placebo group and 123 in the active treatment group) had their first
MRI within 6 months of randomization. Among these patients, 29
examinations could not enter the image-processing phase because of
low quality, and hence, the final sample included 225 patients (116
in the placebo group and 109 in the active treatment group). The
patients randomized who did not participate in the MRI substudy
(n97) were older (mean age 64.0 years [SD11.0] versus 60.4
[SD10.8], P0.007) and were more often women (37.5% versus
22.1%, P0.004) than those who participated. These 2 groups did
not differ significantly for treatment allocation (44.2% of those who
did not participate were assigned to placebo versus 51.6% of those
who participated, P0.23) or for hypertension at baseline (59.6%
versus 50.9%, P0.14). Similar differences were observed when the
group of 192 patients who had both MRI examinations was com-
pared with the 130 patients who did not.
A second MRI examination was scheduled to be performed before
the end of the follow-up, on average 3 years after the initial scan
(range of 24 to 49 months). Follow-up rate was 86% (n192).
Among the 33 patients who did not have a follow-up scan, 14
refused, 13 met 1 of the exclusion criteria, and 6 had died (Figure 1).
Subjects who did not have a follow-up MRI (n33) were on average
older (mean age 68.9 years [SD9.0] versus 59.0 years [SD10.4],
P0.001) and had more frequent severe cerebral WMH on first MRI
(48.5% versus 14.0% respectively, P0.001) than subjects who had
a follow-up MRI (n192). Gender distribution, baseline blood
pressure levels, and intake of antihypertensive medication were
similar in both groups. The follow-up rate was slightly higher for
those who were in the placebo group (89%) than for those who were
in the active treatment group (82%), but the difference was not
significant (P0.14). At each step of the study, the rates of refusals
or dropouts did not differ significantly between the active treatment
and placebo groups.
Magnetic Resonance Imaging
Baseline cerebral MRI was performed with 1.0-Tesla scanners in 5
centers and 1.5-Tesla scanners in 5 other centers. The following
procedures were implemented after visits of the MRI coordinating
team in each center. For each subject, the orbitomeatal line served as
the reference line for brain positioning in the field of view, to ensure
maximum field homogeneity over the volume of interest. A para-
medial sagittal, T1-weighted thick slice was first acquired to delimit
the length of the field of view in the z-axis. A high-resolution,
T1-weighted brain volume was subsequently acquired with a 3D, fast
spoiled gradient echo sequence (3D-FSPGR, 128 1.4-mm-thick
slices, 256256 matrix, 0.90.9 mm2 pixel, 24-cm transversal field
of view). Proton-density/T2-weighted images were obtained with a
fast multislice double-echo 2D axial acquisition (repetition time
3500 ms, time of echo 185 ms, time of echo 2140 ms,
5-mm-thick contiguous slices, 256256 matrix, 0.90.9 mm2 pixel,
24-cm transversal field of view). Image-acquisition parameters were
identical for both the initial and follow-up MRI examinations.
Because the major goal of the present study was to assess on the
follow-up MRI examination the evolution of WMHs, a special
procedure had to be implemented to ensure that image interpretation
conditions were as similar as possible for both examinations in a
given subject. The steps of this procedure were as follows: (1) The
follow-up T2 volume was first aligned to the initial one with the
automatic image registration algorithm.23 (2) Histogram equalization
was then applied to the 2 T2 volumes, thereby ensuring comparable
image characteristics in terms of signal intensity. (3) Finally, a
PC-based, user-friendly graphic interface was developed to allow the
radiologist to visualize side by side the slices of both the initial and
follow-up MRI examinations (Figure 2).
Figure 1. Flowchart of participants in the PROGRESS MRI
substudy.
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WMH Assessment
A trained neuroradiologist (OC) blinded to clinical data and treat-
ment allocation established all the ratings. At first MRI examination,
the magnetic resonance images were rated visually with respect to
the presence of WMH with a modified version of a validated
scale.5,24 This scale provided an overall WMH grade ranging from A
to D, as follows: A, no lesion; B (mild WMH), deep WMH 3 mm
or periventricular hyperintensities5 mm; C (moderate WMH), 1 to
10 deep WMHs (4 to 10 mm) or periventricular hyperintensities (6
to 10 mm); and D (severe WMH), more than 10 deep WMHs (4 to
10 mm) or confluent deep WMHs or periventricular hyperintensities
11 mm. Because of the limited number of subjects, in some
analyses we combined categories B and C and used a 3-level grading
scale. Comparing baseline and follow-up scans on the same screen,
the radiologist also determined the presence of each new WMH that
occurred during follow-up, the volume of which was assessed after
individual delimitation of the WMH on the computer screen. Volume
of incident WMHs was calculated by summing the surfaces of the
WMHs on consecutive T2-weighted images, and the slice thickness
was used as a third dimension. The presence of prevalent stroke scars
was rated by size (small, medium, or large). Stroke scars limited to
the white matter were distinguished from WMHs, because they were
hypointense on T1-weighted images. Volume of stroke scars was not
included in the calculation of volume of prevalent or incident WMH.
Statistical Analysis
All randomized participants who had 2 MRI examinations (n192)
were included in the analysis. For baseline comparisons, we used
simple 2 tests for categorical variables and ANOVA for continuous
variables.
We performed logistic regression to assess the relationship be-
tween treatment and presence of incident WMH at second MRI. We
conducted ANCOVA to compare the total volume of incident
WMHs between the active treatment and placebo groups. For both
logistic regression and ANCOVA, the initial analyses included
adjustment for age, sex, and center. Further adjustments were made
for height, stroke type, baseline blood pressure level, antihyperten-
sive treatment intake, interval (in months) between the 2 MRI scans,
and baseline severity of WMH. To test the hypothesis that the
baseline severity of WMH may modify the relationship between
treatment allocation and total volume of incident WMH, we added
the WMH-by-treatment interaction term to the above model and
tested for its significance. Because the interaction term was signifi-
cant, we performed stratified analysis by baseline severity of WMH.
We also tested interaction between treatment and age, sex, center,
and stroke type. Because distribution of WMH volumes is skewed,
we used log-transformed WMH volumes to test for significance. All
analyses were performed with SAS version 8.02 (SAS Institute Inc).
Results
Table 1 describes baseline characteristics by treatment allo-
cation of all randomized study participants who had the 2
MRI examinations. The age of the study participants ranged
from 35 to 85 years, and approximately 75% of them were
men. At study entry, approximately half of the patients were
taking antihypertensive medications, and 52% of the subjects
had hypertension. There was no significant difference be-
tween the 2 treatment groups for age, gender, and vascular
factors (Table 1). With regard to study regimen, 112 patients
(58%) were given the combination of perindopril and indap-
amide (or their placebos), and 80 were given perindopril
alone (or its placebo).
On baseline MRI, 42% of the patients had no WMH, 26%
had mild WMH, 13% had moderate WMH, and 19% had
severe WMH (Table 2). A stroke scar was visible at cerebral
MRI in 55% of the patients. Among patients with a visible
stroke scar, its size was small (15 mm) in 41%, medium in
30%, and large in 29%. There were no significant differences
for baseline cerebral MRI characteristics between placebo
and active treatment groups. Factors associated with baseline
severity of WMH for the entire sample are shown in Table 3.
There was a significant trend for a relationship between
Figure 2. Illustration of the technique used for MRI assessment.
On the left side of the Figure, there is an axial T2-weighted
image of first MRI examination of a PROGRESS patient. On the
right side, the image is taken from the second examination per-
formed at the end of the follow-up. With registration techniques
and histogram equalization, it was possible to make this second
examination as similar as possible to the first examination, as
seen in the Figure, thus facilitating the comparison between the
2 examinations by the neuroradiologist. Despite the small loss
of resolution in the second examination due to the technique, it
is possible to visualize new lesions close to the left occipital
horn.






Mean age, y (SD) 60.7 (12.2) 60.9 (12.1) 0.89
Male gender, % 77 75 0.67
Age at highest level of education, y (SD) 17.6 (5.9) 17.2 (4.5) 0.56
Mean height, cm (SD) 170.3 (9.0) 168.8 (7.3) 0.22
Mean SBP, mm Hg (SD) 142.2 (19.7) 144.3 (20.0) 0.41
Mean DBP, mm Hg (SD) 87.8 (12.2) 88.2 (11.6) 0.79
Antihypertensive medication (%) 51 48 0.52
Hypertension, %† 50 53 0.65
Current smoker, % 19 20 0.96
History of diabetes, % 15 16 0.97
Mean weekly alcohol consumption (SD)‡ 6.6 (9.7) 5.5 (9.0) 0.37
Type of stroke, %§ 0.65
Ischemic 73 77
Hemorrhagic 11 8
Transient ischemic attack 16 15
SBP indicates systolic blood pressure; DBP, diastolic blood pressure.
*Comparison of active treatment and placebo groups based on 2 test for
qualitative variables and Student’s t test for quantitative variables.
†Systolic blood pressure 160 or diastolic blood pressure 90 mm Hg.
‡In number of standard drinks of alcohol.
§Qualifying (most recent) event for study entry.
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increasing age and severity of WMH. The prevalence of
severe WMH was also associated with antihypertensive drug
treatment at entry and with blood pressure level at random-
ization. Mean SBP was 13 mm Hg higher in the group of
patients who had severe WMH than in those who had no
WMH at entry (Table 3).
The second MRI was performed on average 36 months
after baseline MRI (37 months in the placebo group, 36
months in the active treatment group; P0.10). At the time of
the second MRI, decreases in systolic and diastolic blood
pressure levels compared with baseline measure were signif-
icantly larger in the treated group than in the placebo group.
The mean decrease of systolic blood pressure was
12.5 mm Hg (SD22.0) in the treated group compared with
1.3 mm Hg (SD20.0) in the placebo group (P0.0004), and
the mean decrease of diastolic blood pressure was 8.2
(SD12.3) in the treated group compared with 3.9
(SD15.5) in the placebo group (P0.04). The proportion of
patients who continued to take randomized therapy at the
time of the second MRI was 79% in the active treatment
group and 88% in the placebo group (P0.42).
During follow-up, 24 patients developed new WMH, 16
(16%) in the placebo group and 8 (9%) in the active treatment
group (P0.17; Table 4). Overall, the total volume of new
WMHs was 1.8 mm3 (SE0.5). The mean (SE) volume of
new WMHs increased with baseline grade of WMH, from
0.05 (0.8) for patients who had no WMH at baseline to
1.2 mm3 (1.2) for those who had a mild to moderate grade and
6.5 mm3 (2.0) for patients with a severe baseline grade of
WMH. Other baseline variables were not associated with the
total volume of new WMHs. The total volume of new WMHs
was significantly lower in the active treatment group
(mean0.4 mm3, SE0.8 mm3) compared with the placebo
group (mean2.0 mm3, SE0.7 mm3; P0.012; Table 4).
We found a significant interaction between baseline severity
of WMH and treatment allocation on the total volume of
incident WMH (P0.001). We therefore performed stratified
analysis by severity of WMH at baseline and observed that
the treatment effect on the total volume of new WMH was
particularly marked in patients with severe WMH at baseline
(Table 4). Further adjustments for height, stroke type, base-
line blood pressure level, antihypertensive treatment intake,
interval (in months) between the 2 MRI scans, and baseline
severity of WMH gave similar results (Table 4).
Exclusion of subjects who had a stroke (n20) during
follow-up did not modify the pattern of results. We also
performed separate analyses by study drug regimen
(perindopril-indapamide combination and perindopril single-










Stroke scar size, % 0.86




*Comparison of active treatment and placebo groups based on 2 test.
TABLE 3. Factors Associated With WMH Grade at Baseline









Mean age, y (SD) 55.9 (10.4) 59.7 (9.2) 61.1 (10.5) 65.5 (9.1) 0.0001
Male gender, % 80 76 69 85 0.49
Mean height, cm (SD) 170.6 (7.8) 168.4 (9.0) 168.2 (8.2) 170.1 (8.3) 0.37
Age at highest level of education, y (SD) 18 17 19 17 0.13
Mean SBP, mm Hg (SD) 136.0 (15.6) 144.6 (21.8) 146.6 (19.3) 149.3 (21.7) 0.003
Mean DBP, mm Hg (SD) 85.1 (10.8) 90.0 (13.4) 90.1 (10.8) 88.9 (12.9) 0.07
Antihypertensive medication, % 30 51 58 67 0.006
Current smoker, % 20 21 19 15 0.50
Diabetes, % 13 6 27 22 0.04
Mean weekly alcohol consumption, mean (SD)† 4.9 (7.3) 7.2 (9.6) 5.7 (7.4) 6.2 (9.4) 0.48
Type of stroke, %‡ 0.64
Ischemic 44 27 15 14
Hemorrhagic 50 20 5 25
Transient ischemic attack 45 32 13 10
SBP indicates systolic blood pressure; DBP, diastolic blood pressure.
*P value from 2 test for qualitative variables and ANOVA for quantitative variables.
†In number of standard drinks of alcohol.
‡Qualifying (most recent) event for study entry.
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drug therapy), and the results were similar in the 2 subgroups
(data not shown). Interactions between treatment and sex
(P0.83), age (P0.47), center (P0.96), and stroke type
(P0.55) on the volume of WMH were not significant.
Discussion
In this placebo-controlled, double-blind trial of a blood
pressure–lowering regimen that combined an ACE inhibitor
(perindopril) and a diuretic (indapamide) in patients with a
history of cerebrovascular disease, patients who received
active treatment had a significantly lower total volume of
incident WMH than patients who received placebo over 3
years of follow-up. The beneficial effect of this blood
pressure–lowering regimen remained significant after adjust-
ment for several variables, including age, gender, stroke type,
baseline blood pressure, and severity of WMH at baseline.
We also observed a 43% (95% CI 7% to 89%) risk
reduction of the occurrence of new WMH in the active
treatment group compared with the placebo group, although
the difference did not reach statistical significance (8/89
[9.0%] versus 16/103 [15.5%], respectively; P0.17).
WMHs are strongly associated with hypertension,5,19,25 and
the results of some large observational cohort studies suggest
that patients whose hypertension is better controlled have a
more limited progression of WMH.5,25 The present study, the
first to have implemented an MRI-based assessment of WMH
in a randomized trial, confirms that it is possible to limit
WMH progression with a perindopril-based blood pressure–
lowering regimen in patients with cerebrovascular disease. A
post hoc analysis also indicates that the greatest beneficial
effect of antihypertensive therapy on WMH progression was
observed in the group of patients who had severe WMH at
entry. This result is consistent with previous studies showing
that over time, patients with greater lesion volume at baseline
have a greater increase in the number or total volume of
WMHs.6,17,20,21,26
The present findings must be considered in light of the
limited power of the study. During the mean 3-year follow-up
period, 24 of 192 patients developed new WMH, a ratio
consistent with previous studies,21 but these relatively small
numbers affect the power to detect the effect of treatment.
They also do not allow us to give precise estimates of the
treatment effect on the incidence of WMH or the volume of
incident WMH by regimen (perindopril alone or perindopril
plus indapamide) or by stroke type.7,27 With regard to volume
of WMH, we decided per protocol to measure only the
volume of new WMH. Another option would be to also study
the growth of baseline WMH, because it could participate in
the overall increase in volume of WMH. Although the
question addressed would be slightly different, this option
should be considered in future studies to increase their power
to detect a treatment effect. In our estimation of the volume of
new WMH, we carefully excluded scars caused by stroke that
occurred during follow-up, because the treatment effect for
stroke could mask its effect on WMH. Furthermore, of the 20
patients who had a stroke during follow-up, only 2 had new
WMHs, and exclusion of these patients from the analysis did
not modify the results with regard to meaning and statistical
significance. Selection of patients is a potential limitation of
the present study, because those who agreed to participate in
the MRI substudy were healthier than those who refused. This
selection bias, which is usual in MRI studies, had no effect on
the balanced distribution of the variables between the placebo
and the active treatment arm. Furthermore, because the
strongest treatment effect was seen in patients with the most
severe grades of WMH at baseline, that is, in patients more
likely to refuse than agree to participate, the selection bias
observed is probably conservative. We therefore believe that
this selection had no bearing on the validity of the present
results, although it could have affected the study power.
Despite its limited power, our study has several strengths.
Among the patients included in the selected centers, 87%
(281/322) agreed to participate in the study, and among those
who had their first MRI examination and who could partici-
pate, 93% (192/206) agreed to have a second MRI examina-
tion. Overall, despite deaths and patients who met exclusion
criteria for MRI, the participation rate was 85% (192/225)
between both examinations. The study is further strengthened
by the methods used to estimate the volume of WMH.
Limitations of visual scales to evaluate WMH severity, as
well as WMH changes over time, have been discussed
extensively.28–30 We used a semiautomated method to iden-











Incident WMH, n (%) 24 (13) 16 (16) 8 (9) 0.17 0.10
Mean volume of incident WMH, mm3 (SE) 1.8 (0.5) 2.0 (0.7) 0.4 (0.8) 0.012 0.009
Volume of incident WMH by initial grade
of WMH, mm3 (SE)
No WMH 0.05 (0.8) 0 0.09 (0.8) 0.76 0.81
Mild to moderate WMH 1.2 (1.2) 1.3 (1.0) 0.9 (1.0) 0.58 0.71
Severe WMH 6.5 (2.0) 7.6 (1.0) 0 0.0001 0.0001
*P value generated from logistic regression for qualitative variables or from ANCOVA with adjustment for age, sex,
and center.
†P value generated from logistic regression for qualitative variables or from ANCOVA with adjustment for age, sex,
center, height, stroke type, baseline blood pressure levels, and antihypertensive treatment intake, interval (in number
of months) between the 2 MRI scans, and baseline severity of WMH (if applicable).
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tify incident WMHs and to measure their volume. Special
care was taken in standardizing the quality and reading
conditions of the T2 scans acquired 3 years apart in the same
patient. Finally, this substudy had the same favorable char-
acteristics as the main PROGRESS study in terms of good
adherence to treatment and maintained blood pressure differ-
ence throughout follow-up.
The selection of patients mentioned above limits our ability
to extend the results of this substudy to all patients enrolled in
the PROGRESS trial. The present study showed, in a partic-
ular subset of patients, that it is possible to limit the
progression of WMH. These results now need to be con-
firmed and extended in further clinical trials, such as in
hypertensive patients free of cerebrovascular disease. Our
results could help design such future studies in terms of
number of patients, duration of follow-up, stratification on
baseline severity of WMH, and methods used to estimate the
volume of WMH.
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